Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Storage related haematological and biochemical changes in Plasmodium falciparum infected and sickle cell trait donor blood

BMC Hematology201818:30

https://doi.org/10.1186/s12878-018-0128-x

  • Received: 19 September 2018
  • Accepted: 28 October 2018
  • Published:
Open Peer Review reports

Abstract

Background

In sub-Saharan Africa where sickle cell trait (SCT) and malaria is prevalent, significant proportions of blood donors may be affected by one or more of these abnormalities. The haemato-biochemical properties of SCT and asymptomatic malaria in donor blood have not been evaluated. This study evaluated the haemato-biochemical impact of SCT and asymptomatic malaria infections in citrate-phosphate-dextrose-adenine (CPDA-1) stored donor blood units.

Methods

Fifty-milliliters of sterile CPDA-1 anti-coagulated blood were drained into the sample pouch attached to the main blood bag. Ten units each of sickle cell/malaria negative, sickle cell and malaria positive blood were analyzed. Baseline and weekly haematological profiling and week 1, 3 and 5 concentrations of plasma haemoglobin, % haemolysis, sodium, potassium and chloride and lactate dehydrogenase (LDH) were assayed. Differences between baseline and weekly data were determined using one-way analysis of variance (ANOVA) and Kruskal-Wallis test, whereas differences between baseline parameters and week 1–3 data pairs were determined using paired t-test. P-value < 0.05 was considered statistically significant.

Results

Storage of SCT and malaria infected blood affected all haematological cell lines. In the SCT donors, red blood cells (RBC) (4.75 × 1012/L ± 1.43baseline to 3.49 × 1012/L ± 1.09week-5), haemoglobin (14.45 g/dl ± 1.63baseline to 11.43 g/dl ± 1.69week-5) and haematocrit (39.96% ± 3.18baseline to 33.22% ± 4.12week-5) were reduced. In the asymptomatic malaria group, reductions were observed in RBC (5.00 × 1012/L ± 0.75baseline to 3.72 × 1012/L ± 0.71week-5), haemoglobin (14.73 g/dl ± 1.67baseline to 11.53 g/dl ± 1.62week-5), haematocrit (42.72% ± 5.16baseline to 33.38% ± 5.80week-5), mean cell haemoglobin concentration (35.48 g/dl ± 1.84baseline to 35.01 g/dl ± 0.64week-5) and red cell distribution width coefficient of variation (14.81% ± 1.54baseline to 16.26% ± 1.37week-5). Biochemically, whereas plasma LDH levels significantly increased in asymptomatic malaria blood donors (319% increase at week 5 compared to baseline), SCT blood donors had the most significant increase in plasma potassium levels at week 5 (382% increase). Sodium ions significantly reduced in SCT/malaria negative and sickle cell trait blood at an average rate of 0.21 mmol/L per day. Moreover, elevations in lymphocytes-to-eosinophils and lymphocytes-to-neutrophils ratios were associated with SCT and malaria positive blood whilst elevation lymphocytes-to-basophils ratio was exclusive to malaria positive blood.

Conclusion

Severe storage lesions were significant in SCT or malaria positive donor blood units. Proper clinical evaluation must be done in prospective blood donors to ensure deferral of such donors.

Keywords

  • Sickle cell trait donor
  • Asymptomatic malaria donor
  • % haemolysis
  • Storage lesions
  • Plasma haemoglobin
  • Biochemical changes
  • Blood transfusion

Background

There are two major outcomes of Plasmodium infections, thus symptomatic and asymptomatic infections. Symptomatic infections occur in patients with compromised anti-disease immunity [1] and asymptomatic infections occur in individuals with competent malaria immunity [2]. Despite being asymptomatic, parasites may be present in red blood cells, but at low density and can persist for many months [3]. Prevalence of asymptomatic Plasmodium infections differs from one geographical region to another. In Brazil, Solomon Islands and Cambodia, asymptomatic malaria has been found to be 37.5, 82.2 and 92% respectively [46]. In Africa, the prevalence of asymptomatic malaria in blood donors in Ghana has been found to be 10.0% [7]. In Cameroon, Senegal, Benin and Nigeria, asymptomatic malaria parasitaemia in blood donors have been found to be 27.54% [8], 65.3% [9], > 30% [10] and 40% [11] respectively.

Sickle cell haemoglobin result when valine substitutes for glutamic acid at position 6 of the β-globin chain. This mutation consequently changes the physico-chemical properties of the haemoglobin molecule [12]. A person who inherits haemoglobin S from one parent and haemoglobin A (normal gene) from the other has a sickle cell trait (SCT) or is said to be a carrier of sickle cell disease [13]. The prevalence of sickle cell trait (SCT) is highest in Africans and people of African descent. In Africa, Nigeria probably has the highest number of people with SCT as close to 30% of the population carry haemoglobin S gene [14]. Liberia, Ghana and Uganda have 10–15% of their population being carriers of haemoglobin S gene [13, 15, 16]. Cameroon and Gabon have haemoglobin S gene prevalence of 19 and 22%, respectively [17, 18]. SCT individuals are clinically healthy to donate blood [19]. Populations with high prevalence of sickle cell trait and asymptomatic Plasmodium falciparum infections can result in high number of healthy blood donors with sickle cell trait and/or asymptomatic Plasmodium infections. In Kenya and Nigeria, proportion of their blood donor population who were sickle cell carriers were 3.9 and 27.1% respectively [20, 21]. In Ghana, studies done in Brong Ahafo and Greater Accra regions reported prevalence of SCT in blood donors to be 12.5 and 11.3% respectively [12, 22].

Majority of the blood banks in SSA still practice whole blood banking [23, 24]. Although donated blood units are stored in anticoagulants supplemented with phosphate, dextrose, and/or adenine to assure long-term viability, storage lesions are inevitable when blood is stored for long periods [25]. RBC storage lesions include decreased RBC stability, alterations in various metabolites and the metabolic status of the cell, including decrease of intracellular adenosine triphosphate (ATP) and 2,3-biphosphoglycerate (2,3 BPG) [2628]. These changes in RBC during storage have been known for years but the exact changes conferred on blood collected from SCT donors and those infected with Plasmodium parasites are unknown. The aim of this study therefore was to evaluate, for the first time, the haematological and biochemical variations in sickle cell trait blood and blood infected with Plasmodium falciparum stored in CPDA-1 anticoagulant up to 35 days.

Methods

Study design

This cross-sectional laboratory based experimental study was done in sterile blood units. Donors were selected according to Medical History Guide for Donor Selection [29].

Donor selection, phlebotomy and specimen collection

The selections of the healthy blood donors were double-blinded as researchers and National Blood Service Ghana staff could not link the study specimens to any donor. Participant consent form was signed by all participated donors. Blood was collected from each of the donors following a modification of the technique described by Cheesbrough [25]. For the purpose of the study, 7 ml of the CDPA-1 anticoagulant was allowed into the sample pouch attached to the main blood bag, which was filled with the initial 50 ml of whole blood. The rest of the whole blood was directed into the main blood bag.

Inclusion criteria

Donor blood included in the study were TTIs-negative blood with baseline biochemical parameters that fell within these ranges; haemoglobin 12.5–18.00 g/dl, plasma haemoglobin-0 g/dl, percentage haemolysis-0.0%, plasma sodium, potassium, chloride and LDH that fell within these respective ranges 135-145mmo/l, 3.0–5.2 mmol/l, 95-108 mmol/l and 100-250 U/L.

Laboratory procedures

Post-phlebotomy laboratory procedures were done as follows: 5 ml of well mixed whole blood was aspirated into plain glass vacutainer tubes (All-Pro, Dusseldorf, Germany). Portion of the blood was used to screen for transfusion-transmitted infections (TTIs) using fourth generation enzyme immuno-assay (Abnova, Taiwan). The ELISA microtitre plate wells were pre-coated with hepatitis B surface monoclonal antibodies, gp36/gp41, hepatitis C antigens (core, NS3 and NS5) and Treponema pallidum antigens for qualitative detection of hepatitis B virus, HIV I&II, hepatitis C virus and Treponema pallidum respectively. Donor screening of sickle cells was done as described by Antwi-Baffour [13] whilst phenotyping was done in alkaline medium (pH = 8.6). Separation of haemolysate was done on cellulose acetate paper using 250 V voltage and 50 mA current for 30 min. The separated haemoglobin molecules were interpreted against pooled haemoglobin AFSC controls. Screening of malaria was done with PfHRP-2/Pf-LDH SD Bioline rapid diagnostic test kit (Gyeonggi-do, Republic of Korea). The kit detected Plasmodium falciparum specific HRP-2 proteins and lactate dehydrogenase enzymes. Five microliters of whole blood were dropped on the sample column of the rapid test kit. Four drops of assay diluent (PfHRP-2/Pf-LDH SD Bioline, Korea) were added to the buffer window of the kit. Results were read after 15 min. Baseline haematological parameters using 5-part differential Urit-5160 (Guangxi, China), plasma electrolytes (sodium, potassium and chloride) measured by FT-320 electrolyte analyzer (China), lactate dehydrogenase (measured by PKL-125 Italia fully automated chemistry analyzer using ELItech LDH kinetic reagent, France), plasma haemoglobin (Urit-5160, China) and percentage haemolysis calculated by using formulae used by Sawant et al. [30] was done on same day of blood collection (baseline). The donor whole blood study samples were stored in the blood bank refrigerator (Fiocchetti Scientific Refrigerator, Italy) for 5 weeks. Internal storage temperature was taken twice daily. Haematological parameters were determined weekly for 5 weeks whilst plasma haemoglobin, % haemolysis, plasma electrolytes and LDH were measured at the end of week 1, week 3 and week 5.

Data processing and statistical analysis

Baseline and weekly data was entered into Microsoft Excel 2010. Statistical analysis was done by SPSS Version 24 (Chicago, IL, USA). Based on SCT status and/or asymptomatic malaria infection status, participants were grouped into three: SCT blood donors, asymptomatic malaria blood donors and no SCT/asymptomatic malaria blood donors for subsequent analysis. Differences between baseline and the 5 weeks haematological profile and biochemical data set were determined by one-way analysis of variance (ANOVA) and Kruskal-Wallis test statistical models. Differences between baseline haematological parameters and week 1 to 3 data pair were determined by paired student T-test. P-value of < 0.05 was considered statistically significant.

Results

Storage related changes in TWBC and WBC differential counts

The study recorded significant changes in total white blood cells (TWBC) and WBC differential in all the three donor groups (Table 1). There were consecutive reductions in TWBC and neutrophil proportion in all donor groups. Whereas the largest significant TWBC reduction occurred in the sickle cell/malaria negative group (62.3% reduction in week 5), the largest significant reduction in neutrophil% occurred in the SCT donors (53.9% reduction in week 5). However, there were successive increases in %lymphocytes, basophils and monocytes in all donor groups when weekly estimates were compared to baseline values. Whereas the highest increase in %lymphocytes occurred in the sickle cell/malaria negative donors (84.3% increase compared to baseline), the highest %monocyte increase occurred in the SCT donor group (75.6% increase compared to baseline). Additionally, although there was a consecutive reduction in %eosinophil count in the SCT group, the changes in %eosinophil count fluctuated in the sickle cell/malaria negative, and the asymptomatic malaria donor groups.
Table 1

Leukocytes and percentage differential storage changes in donor blood

TWBC and differentials

Baseline Mean

Week 1 Mean (%∆)

Week 2 Mean (%∆)

Week 3 Mean (%∆)

Week 4 Mean (%∆)

Week 5 Mean (%∆)

P-value

Sickle cell/malaria negative donor blood

 TWBCx109/L

5.63

3.89(−30.9)

2.90(−48.4)

2.49(−55.7)

2.27(− 59.6)

2.09(−62.3)

0.001*,a

 Neut %

66.18

60.09(− 9.2)

52.77(−20.2)

49.49(− 25.2)

44.21(− 33.2)

40.88(− 38.2)

0.054b

 Lymp %

27.28

33.42(22.5)

39.83(46.0)

41.92(53.6)

46.94(72.0)

50.28(84.3)

0.092b

 Eos %

3.03

2.73(−9.9)

2.42(−20.1)

3.32(9.5)

3.00(−0.9)

3.49(15.2)

0.845a

 Mon %

3.27

3.52(7.6)

4.64(41.9)

4.94(51.1)

5.50(68.2)

4.96(51.6)

0.009b

 Bas %

0.24

0.25(4.1)

0.35(45.8)

0.33(37.5)

0.35(45.8)

0.39(62.5)

0.033b

Sickle cell trait donor blood

 TWBCx109/L

6.36

5.08 (−20.1)

4.42 (−30.5)

4.24 (−33.3)

3.74 (−41.2)

3.57 (−43.8)

0.001*,b

 Neut %

56.26

50.91 (−9.5)

39.58(−29.6)

32.64 (−41.9)

31.99 (− 43.1)

25.90 (− 53.9)

0.001*,b

 Lymp %

37.50

43.06 (14.8)

51.48 (37.3)

61.46 (63.9)

62.79 (67.4)

66.28 (76.7)

0.001*,1

 Eos %

3.34

2.45 (−26.6)

2.50 (− 25.1)

1.56 (−53.3)

1.69 (−49.4)

2.77 (−17.0)

0.020a

 Mon %

2.71

3.59 (32.4)

3.94 (45.4)

4.02 (48.3)

3.24 (19.5)

4.76 (75.6)

0.179b

 Bas %

0.20

0.20 (0.0)

0.38 (90.0)

0.32 (60.0)

0.30 (50.0)

0.29 (45.0)

0.069b

Asymptomatic malaria donor blood

 TWBCx109/L

6.08

4.49 (−26.1)

4.13 (−32.1)

3.77 (−37.9)

3.54 (−41.7)

3.21 (−47.2)

0.001a

 Neut %

72.09

60.89 (−15.5)

47.78 (−33.7)

39.79 (−44.8)

42.91 (−40.4)

36.07 (− 49.9)

0.001*,b

 Lymp %

31.67

32.53 (2.7)

45.65 (44.1)

52.53 (65.8)

49.52 (56.3)

55.63 (75.6)

0.001*,b

 Eos %

2.38

2.50 (5.0)

2.01 (−15.5)

2.26 (−5.0)

2.39 (0.4)

2.69 (13.0)

0.265a

 Mon %

3.56

3.72 (4.5)

4.68 (31.4)

5.08 (42.6)

4.57 (28.4)

5.29 (48.6)

0.095b

 Bas %

0.30

0.36 (20.0)

0.33 (10.0)

0.34 (13.3)

0.31 (3.3)

0.32 (6.6)

0.804a

Abbreviations: TWBC = total white blood cells, Neut = Neutrophils, Lymp = Lymphocytes, Eos = Eosinophils, Mon = Monocytes, Bas = Basophils, % = Percent, L = Liter, ANOVA = Analysis of variance, SD = Standard deviation

*p values less than 0.001, ap-value determined by Kruskal-Wallis H test, bp-value determined by one-way ANOVA

Storage related changes in RBC and RBC indices

This study also found significant changes in RBC count and RBC indices in all the three donor groups (Table 2). In all donor groups, there were consecutive reductions of RBC count, haemoglobin level, and HCT in all successive weekly estimations compared to baseline values. Whereas the most significant reduction in RBC count occurred in the SCT blood donor group, (26.5% decrease compared to baseline), the highest reductions in haemoglobin and HCT occurred in the sickle cell/malaria negative blood donor group [26.5% (Hb), and 25.2% (HCT) reductions compared to baseline]. Also, RDW-CV% values consecutively increased in all donor groups with respect to successive weekly measurement. However, whereas weekly MCV and MCH values consistently decreased in asymptomatic malaria donor group, these values fluctuated in SCT or sickle cell/malaria negative donor groups.
Table 2

RBC and RBC indices storage changes in donor blood

RBC and RBC indices

Baseline Mean

Week 1 Mean (%∆)

Week 2 Mean (%∆)

Week 3 Mean (%∆)

Week 4 Mean (%∆)

Week 5 Mean (%∆)

P-values

Sickle cell and malaria negative donor blood

 

 RBC (×1012/L)

4.72

4.27 (−9.5)

4.08 (− 13.5)

4.03 (− 14.6)

3.98(−15.6)

4.04 (− 14.4)

0.147a

 Hb (g/dl)

13.17

11.35 (−13.8)

10.49 (− 20.3)

9.97 (− 24.3)

10.06 (−23.6)

9.74 (−26.0)

0.022a

 HCT (%)

37.54

33.52 (−10.7)

28.83 (− 23.2)

28.52 (−24.0)

28.48(− 24.1)

28.06(− 25.2)

0.013a

 MCV (fL)

75.88

76.99 (1.5)

75.34 (−0.7)

74.37 (−1.9)

74.67 (−1.6)

75.22 (− 0.9)

0.952a

 MCH (pg)

26.70

26.23 (−1.7)

27.61 (3.4)

25.85 (−3.1)

26.39 (−1.1)

26.14 (−2.0)

0.924a

 MCHC (g/dl)

32.47

31.39 (−3.3)

33.58 (3.4)

31.90 (−1.7)

32.45 (−0.6)

31.92 (−1.6)

0.932a

 RDW_CV (%)

14.14

14.14 (0.0)

14.20 (0.4)

15.02 (6.2)

14.63 (3.4)

14.76 (4.3)

0.486b

 RDW_SD (fL)

32.38

32.38 (0.0)

33.55 (3.6)

31.76 (−1.9)

32.14 (−0.7)

30.17 (−6.8)

0.756b

Sickle cell trait donor blood

 RBC (×1012/L)

4.75

4.06 (−14.5)

3.58 (−24.6)

3.57 (−24.8)

3.56 (−25.0)

3.49 (−26.5)

0.016a

 Hb (g/dl)

14.45

12.84 (−11.1)

12.47 (−13.7)

11.47 (−20.6)

11.57 (− 19.9)

11.43 (−20.8)

0.002a

 HCT (%)

39.96

36.75 (−8.0)

33.34 (−16.5)

33.29 (−16.7)

32.55 (− 18.5)

33.22 (− 16.8)

0.005a

 MCV (fL)

82.54

86.71 (5.0)

82.02 (−0.6)

81.27 (−1.5)

82.03 (− 0.61)

82.95 (0.4)

0.573a

 MCH (pg)

30.36

30.29 (−0.2)

30.39 (0.3)

28.54 (−5.9)

29.12 (−4.0)

28.43 (−6.3)

0.424a

 MCHC (g/dl)

36.75

34.99 (−4.7)

37.08 (0.9)

34.96 (− 4.8)

35.50 (−3.4)

34.30 (−6.6)

0.001a

 RDW_CV (%)

14.75

14.75 (0.0)

14.91 (1.0)

15.30 (3.7)

15.03 (1.8)

23.68 (60.5)

0.518b

 RDW_SD (fL)

35.59

35.59 (0.0)

36.54 (2.6)

33.80 (5.0)

34.06 (4.2)

31.83 (10.5)

0.082b

Asymptomatic malaria donor blood

 RBC (×1012/L)

5.00

4.48 (−10.4)

4.02 (−19.6)

4.00 (−20.0)

3.96 (−20.8)

3.72 (−25.6)

0.001*,a

 Hb (g/dl)

14.73

13.06 (−11.3)

12.12 (−17.7)

11.82 (− 19.7)

11.98 (− 18.6)

11.53 (−21.7)

0.001*,a

 HCT (%)

42.72

38.83 (−9.1)

34.04 (−20.3)

34.32 (− 19.6)

34.33 (−19.6)

33.38 (−21.8)

0.001*,a

 MCV (fL)

89.15

87.66 (−1.6)

82.04 (−7.9)

81.81 (−8.2)

82.68 (−7.2)

83.31 (−6.5)

0.067a

 MCH (pg)

30.85

29.42 (−4.6)

29.66 (−3.8)

28.13 (−8.8)

29.20 (−5.3)

29.15 (−5.5)

0.320a

 MCHC (g/dl)

35.48

33.57 (−5.3)

36.22 (2.0)

34.45 (2.9)

35.38 (−0.2)

35.01 (−1.3)

0.002b

 RDW_CV (%)

14.81

14.81 (0.0)

15.80 (6.6)

16.39 (10.6)

16.16 (9.1)

16.26 (9.7)

0.024a

 RDW_SD (fL)

36.53

36.53 (0.0)

35.75 (−2.1)

33.82 (−7.4)

34.49 (−5.5)

34.49 (−5.5)

0.267a

Abbreviations: RBC = Red blood cells, Hb = Haemoglobin, HCT = Haematocrit, MCV = Mean cell volume, MCH = Mean cell haemoglobin, MCHC = Mean cell haemoglobin concentration, RDW_CV = Red cell distribution width coefficient of variation, RDW_SD = Red cell distribution width standard deviation, L = Litre, fL = Fentolitre, pg = picogram

*p values less than 0.001; ap-value determined by one-way ANOVA; bp-value determined by Kruskal-Wallis H test

Storage related changes in platelets and platelet indices

Changes in platelet count and related platelet indices were also observed in the donor population (Table 3). Consecutively, weekly platelet count estimates successively decreased in all blood donor groups; the highest significant reduction occurring in asymptomatic malaria blood donor group (49.9% decrease compared to baseline). Also, whereas weekly MPV and P_LCR successively increased in sickle cell/malaria negative and asymptomatic malaria donor group, the levels of these measurements fluctuated in the SCT blood donor group.
Table 3

Platelet and platelet indices storages changes in donor blood

 

Baseline Mean

Week 1 Mean (%∆)

Week 2 Mean (%∆)

Week 3 Mean (%∆)

Week 4 Mean (%∆)

Week 5 Mean (%∆)

F

P-value

Sickle cell and malaria negative donor blood

 Plt (×109/L)

224.10

199.55(10.9)

171.10(23.6)

162.60(27.4)

167.40(25.3)

139.30(37.8)

4.09

0.003

 MPV (fL)

8.45

9.05(7.1)

9.93(17.5)

9.71(14.9)

9.17(8.5)

10.10(19.5)

8.18

0.001*

 PDW (fL)

12.74

12.41(2.5)

13.93(9.3)

13.00(2.0)

11.98(5.9)

13.63(6.9)

1.00

0.425

 PCT (%)

0.18

0.16(11.1)

0.17(5.5)

0.15(16.6)

0.15(16.6)

0.13(27.7)

1.09

0.374

 P_LCR (%)

18.15

20.11(10.7)

21.86(20.4)

22.15(22.0)

19.21(5.8)

24.18(33.2)

1.24

0.304

Sickle cell trait donor blood

 Plt (×109/L)

225.90

214.10(5.2)

185.20(18.0)

189.40(16.1)

207.80(8.0)

167.61(25.8)

1.25

0.301

 MPV (fL)

8.69

8.53(1.8)

9.83(13.1)

9.78(12.5)

9.83(13.1)

10.45(20.2)

3.85

0.005

 PDW (fL)

12.31

12.03(2.2)

13.89(12.8)

13.75(11.6)

13.72(11.4)

15.54(26.2)

1.55

0.189

 PCT (%)

0.19

0.19(0.0)

0.18(5.2)

0.18(5.2)

0.20(5.2)

0.18(5.2)

0.31

0.903

 P_LCR (%)

16.62

16.19(2.5)

20.02(20.4)

21.65(30.2)

20.35(22.4)

24.28(46.0)

2.09

0.080

Asymptomatic malaria donor blood

 Plt (×109/L)

191.90

141.30(26.3)

132.70(30.8)

118.40(38.3)

106.80(44.3)

96.10(49.9)

7.47

0.001*

 MPV (fL)

8.59

8.59(0.0)

9.87(14.9)

9.93(15.6)

9.10(5.9)

10.19(18.6)

2.52

0.040

 PDW (fL)

13.90

13.90(0.0)

14.28(2.7)

14.75(6.1)

12.25(11.8)

15.98(14.9)

1.49

0.208

 PCT (%)

0.15

0.15(0.0)

0.16(6.6)

0.15(0.0)

0.16(6.6)

0.14(6.6)

0.41

0.835

 P_LCR (%)

19.48

19.48((0.0)

22.19(13.9)

22.17(13.8)

21.40(9.8)

26.89(38.0)

1.33

0.265

Abbreviations: Plt = Platelets, PMV = Mean platelet volume, PDW=Platelet distribution width, PCT = Plateletcrit, P_LCR = Platelet large cell ratio

*p values less than 0.001

Storage related changes in leukocyte ratios

There was progressive increase in lymphocyte-to-eosinophils ratio (LER) in the three blood donor groups but the differences in the SCT/malaria negative group were not significant (%∆ 4.0–20.7%, F = 2.363, p = 0.052) whilst significant differences were seen in the SCT (%∆ 55.9–178%, F = 5.16, p = < 0.05) and the malaria positive donor group (%∆ 35.5–514.7%, F = 4.46, p = < 0.05). In addition to LER, significant increase in lymphocyte-to-basophils ratio (LBR) was observed in malaria positive donor group (%∆ 25.3–151.9%, F = 5.11, p = < 0.05) but not in SCT group (F = 0.73, p = 0.602) and SCT/malaria negative group (F = 0.34, p = 0.882). There were gradual increases in lymphocytes-to-monocytes ratio (LMR) in both the SCT and the malaria positive group but the differences between the values were not significant. Lymphocyte-to-neutrophil ratio (LNR) increased in the three groups but significant increases were seen in SCT (29.1–308.8%, F = 4.53, p = 0.001) and malaria positive blood (75–437.5%, F = 10.9, p < 0.05) (Table 4).
Table 4

Storage related changes in leucocyte ratios

Leukocyte ratio

Baseline Mean

Week 1 Mean(%∆)

Week 2 Mean(%∆)

Week 3 Mean(%∆)

Week 4 Mean(%∆)

Week 5 Mean(%∆)

F

P-value

Sickle cell and malaria negative donor blood

 LER

19.8

20.6(4.0)

20.3(2.5)

21.2(7.1)

22.5(13.6)

23.9(20.7)

2.36

0.052

 LMR

9.7

10.0(3.1)

9.0(7.2)

8.7(10.3)

10.2(5.2)

10.0(3.1)

0.42

0.828

 LBR

184

205(11.4)

128(30.4)

130(29.3)

150(18.5)

149(19.0)

0.34

0.882

 LNR

0.73

0.83(13.7)

1.12(53.4)

1.17(60.3)

1.33(82.2)

1.88(157.5)

1.44

0.222

Sickle cell trait donor blood

 LER

11.8

18.4(55.9)

26.8(127.1)

36.1(205.9)

38.5(226.3)

32.8(178.0)

5.16

0.001*

 LMR

12.3

13.1(6.5)

14.2(15.4)

16.9(37.4)

22.4(82.1)

13.9(13.0)

1.95

0.100

 LBR

198

177(10.6)

141(28.8)

169(14.6)

183(7.6)

169(14.6)

0.73

0.602

 LNR

0.79

1.02(29.1)

1.42(79.8)

2.22(181.0)

2.83(258.2)

3.23(308.8)

4.53

0.001

Asymptomatic malaria donor blood

 LER

6.8

9.2(35.3)

19.3(183.8)

19.0(179.4)

23.0(238.2)

41.8(514.7)

4.46

0.001

 LMR

5.9

8.7(47.5)

10.6(79.7)

11.3(91.5)

10.6(79.7)

10.8(83.1)

2.07

0.083

 LBR

79

99(25.3)

127(60.8)

175(121.5)

181(129.1)

199(151.9)

5.11

0.001*

 LNR

0.32

0.56(75.0)

1.07(234.4)

1.42(343.7)

1.27(296.9)

1.72(437.5)

10.9

0.001*

Abbreviations: LER-lymphocytes-to-eosinophils ratio, LMR-lymphocytes-to-monocytes ratio, LBR-lymphocytes-to-basophils ratio, LPR-lymphocyte-to-platelets ratio, LNR-lymphocytes-to-neutrophils ratio

*p-value less than 0.001

Moreover, when the weekly estimates in haematological parameters were compared to baseline using paired t-test analyses, most of the significant changes occurred in the SCT blood donors or the asymptomatic malaria positive blood donors (Additional file 1: Table S1).

Effect of storage on haemolytic and biochemical parameters in donor blood

The storage lesions related to haemolytic and biochemical parameters presented in Table 5. The plasma haemoglobin and %haemolysis consecutively increased with the successive weekly estimations in all blood donor groups. Additionally, weekly LDH and plasma potassium levels consecutively increased in weekly estimates compared to baseline in all blood donor groups. Whereas the most significant increase in LDH occurred in asymptomatic malaria blood donor group (319% increase over baseline), the most significant increase in plasma potassium levels occurred in SCT blood donor group (382% increase over baseline levels). However, weekly plasma sodium and chloride levels successively decreased in all blood donor group; the highest significant reductions occurring in asymptomatic malaria blood donor group [10.0% (sodium) and 21.3% (chloride) decreases compared to baseline].
Table 5

Analysis of haemolytic and biochemical parameters in donor blood stored for baseline, week 1, week 3 and week 5

Haemolytic parameters

Baseline Mean

Week 1 Mean (%∆)

Week 3 Mean (%∆)

Week 5 Mean (%∆)

P-value

Sickle cell and malaria negative donor blood

 Plasma Hb (g/dl)

0.00

0.10

0.11(9.1)c

0.21(52.4)c

0.001*,a

 % Haemolysis

0.00

0.52

0.75(30.7)c

1.44(63.9)c

0.001*,a

 LDH (U/L)

199.40

319.20 (60.1)

428.00 (114.6)

522.70 (162.1)

0.001*,a

 Potassium (mmol/L)

4.14

5.65 (56.5)

7.72 (86.5)

10.03(142.3)

0.001*,b

 Sodium (mmol/L)

137.94

134.52 (−2.5)

130.00 (−5.7)

126.33 (−8.4)

0.001*,a

 Chloride (mmol/L)

98.66

89.06 (−3.5)

84.98 (−13.9)

83.55 (−15.3)

0.001*,b

Sickle cell trait donor blood

 Plasma Hb (g/dl)

0.00

0.24

0.37(35.1)c

0.46(47.8)c

0.001*,b

 % Haemolysis

0.00

1.16

2.08(44.2)c

2.62(55.7)c

0.001*,a

 LDH (U/L)

207.10

329.20 (59.0)

491.60 (137.4)

610.40 (194.7)

0.001*,a

 Potassium (mmol/L)

4.27

6.95 (62.8)

12.14 (184.3)

20.58 (382.0)

0.001*,a

 Sodium (mmol/L)

139.51

136.74 (−2.0)

133.67 (−4.2)

130.35 (−6.5)

0.001*,a

 Chloride (mmol/L)

99.63

90.77 (−8.9)

83.99 (− 15.7)

78.50 (−21.2)

0.001*,b

Asymptomatic malaria donor blood

 Plasma Hb (g/dl)

0.00

0.22

0.26(15.4)c

0.32(31.3)c

0.001*,a

 % Haemolysis

0.00

1.00

1.46(31.5)c

1.90(47.3)c

0.001*,a

 LDH (U/L)

192.30

418.70 (117.7)

596.60 (210.4)

806.70 (319.5)

0.001*,b

 Potassium (mmol/L)

4.38

8.38 (91.3)

11.66 (166.2)

15.01 (242.7)

0.001*,b

 Sodium (mmol/L)

140.72

135.17 (−3.9)

130.16 (−7.5)

125.60 (−10.0)

0.001*,a

 Chloride (mmol/L)

100.62

91.00 (−9.6)

85.71 (−14.8)

79.21 (−21.3)

0.001*,a

Abbreviations: LDH = Lactate dehydrogenase, SD = Standard deviation, Hb = Haemoglobin

*p values less than 0.001, ap-value determined by Kruskal-Wallis H test, bp-value determined by one-way ANOVA, c %Δ calculated with respect to week 1 mean values

Comparison of haemolytic and biochemical parameters across blood donor groups

The storage lesions in donor blood were quantitatively compared across the groups with respect to the weeks in storage (Table 6). Plasma haemoglobin and %haemolysis were significantly higher in SCT blood donors with respective weekly measurements compared to the other blood donor groups. However, respective weekly plasma LDH levels were significantly higher in asymptomatic malaria blood donor group compared to respective values in the other blood donor groups. Additionally, although baseline plasma potassium levels were comparable in all blood donor groups, weekly plasma potassium levels were respectively higher in asymptomatic malaria or SCT blood donor group compared to sickle cell and malaria negative blood donor group. Moreover, plasma sodium and chloride significantly decreased in the asymptomatic malaria group compared to the other groups.
Table 6

ANOVA analysis of inter-donor category biochemical and haemolytic parameters

Parameters

Sickle cell/malaria negative donors Mean ± SD

Sickle cell trait donors Mean ± SD

Asymptomatic malaria donors Mean ± SD

F

P-value

Baseline

 Plasma Hb

0.00

0.00

0.00

  

 % haemolysis

0.00

0.00

0.00

  

 LDH (U/L)

202.45 ± 20.51

202.90 ± 18.91

173.20 ± 63.74

1.76

0.188

 Potassium (mmol/L)

4.15 ± 0.70

4.22 ± 0.71

4.01 ± 1.50

0.39

0.681

 Sodium (mmol/L)

138.44 ± 2.40

139.52 ± 2.54

126.37 ± 44.53

3.16

0.057

 Chloride (mmol/L)

98.78 ± 1.66

99.88 ± 1.78

90.37 ± 31.87

2.68

0.085

Week 1

 Plasma Hb

0.10 ± 0.00

0.25 ± 0.13

0.20 ± 0.09

23.6

0.001*

 % haemolysis

0.51 ± 0.05

1.12 ± 0.27

1.01 ± 0.35

20.7

0.001*

 LDH (U/L)

318.36 ± 29.30

346.00 ± 78.68

370.90 ± 137.89

14.6

0.001*

 Potassium (mmol/L)

5.54 ± 0.41

7.02 ± 1.15

8.46 ± 0.75

33.6

0.001*

 Sodium (mmol/L)

134.90 ± 3.06

136.95 ± 2.88

121.09 ± 42.80

1.16

0.326

 Chloride (mmol/L)

89.60 ± 3.12

90.53 ± 4.19

81.74 ± 28.74

1.47

0.246

Week 3

 Plasma Hb

0.11 ± 0.03

0.39 ± 0.12

0.23 ± 0.11

22.2

0.001*

 % haemolysis

0.76 ± 0.35

2.21 ± 0.62

1.37 ± 0.41

17.3

0.001*

 LDH (U/L)

436.36 ± 46.31

491.10 ± 47.17

605.77 ± 61.98

33.0

0.001*

 Potassium (mmol/L)

8.05 ± 1.39

12.02 ± 1.61

11.83 ± 1.47

40.3

0.001*

 Sodium (mmol/L)

130.88 ± 4.23

133.45 ± 3.42

129.00 ± 3.51

3.74

0.035

 Chloride (mmol/L)

85.61 ± 3.91

83.37 ± 3.44

85.37 ± 2.85

0.73

0.487

Week 5

 Plasma Hb

0.20 ± 0.04

0.48 ± 0.19

0.28 ± 0.14

8.84

0.001*

 % haemolysis

1.46 ± 0.51

2.75 ± 1.00

1.78 ± 0.65

4.48

0.001*

 LDH (U/L)

536.09 ± 58.71

631.90 ± 109.29

798.00 ± 64.38

13.0

0.001*

 Potassium (mmol/L)

11.35 ± 4.46

19.48 ± 2.86

15.18 ± 1.98

8.25

0.001*

 Sodium (mmol/L)

127.64 ± 6.00

129.62 ± 5.17

124.73 ± 4.79

9.70

0.001*

 Chloride (mmol/L)

84.27 ± 4.29

77.81 ± 4.31

78.61 ± 3.44

1.22

0.309

Abbreviations: LDH = Lactate dehydrogenase, SD = Standard deviation, Hb = Haemoglobin

*p-values less than 0.001

Discussion

Preservation and long term storage of red blood cells is essential for continuous supply of safe blood for clinical use [24]. Previous studies have found deleterious storage effect on blood cell morphology and functions [3133]. This study found similar trend of storage lesion in whole blood stored up to 5 weeks but the changes were more pronounced in blood collected from sickle cell trait (SCT) donors or donors infected asymptomatically with malaria parasites. In the three groups, gradual reduction in total white cells and neutrophils and progressive increase in lymphocytes were observed; a phenomenon that was previously observed by Adias [24]. This observation probably can be due to cell loss and cytotoxic effect of histamine and cytokines released by neutrophils [34]. TWBC, neutrophils and eosinophils cells lost were more evident in the SCT or asymptomatic malaria positive stored blood than sickle cell and malaria negative blood. It was observed that lymphocytes to eosinophils, monocytes, basophils and neutrophils ratios were elevated in the three groups but in all cases significant elevations occurred in SCT and malaria positive donor blood. Insignificant elevations were observed in SCT/malaria negative blood. Elevation in LER, LMR, LBR and LNR values occurred as a result of progressive elevations in mean lymphocytes percentages and reduction in mean absolute eosinophils, monocytes, basophils and neutrophils. This predisposes blood recipients to bacterial invasion and increased proliferation of pathogenic bacterial [35, 36]. Fever is a common symptom of sepsis [37]. Donor blood with high LER, LMR, LBR and LNR could cause pathogen induced acute or delayed febrile reactions in recipients with low leukocyte count.

In sickle cell and malaria negative group, red blood cells were relatively stable during storage but in the SCT or asymptomatic malaria donor group, there were significant reduction in red blood cells, haemoglobin and haematocrit. These haematological changes corresponded with gradual increases in plasma haemoglobin due to increased red cell breakdown as well as gradual elevation of potassium ions and lactate dehydrogenase during storage. These observations could be as a result of haemoglobin S erythrocytes fragility subsequent to polymerization of haemoglobin S and reduced deformability and loss of red cell elasticity during storage due to low oxygen tension and low pH storage medium [3840] on the one hand, as well as metabolically active intra-erythrocytic Plasmodium parasites could account for these haematological changes. Malaria parasites have been found to be viable in stored blood for at least the first 14 days [41]. When one malaria parasite per microliter of blood is found, that converts to about 500,000 red cells parasitized in a unit of blood [42]. These viable parasites are enough to cause significant haematological derangement in the blood of an infected healthy donor during storage. One of the goals of haemo-transfusion is to restore tissue oxygenation [43]. Stored blood from SCT and asymptomatic malaria donors may develop storage lesions over time due to polymerization of haemoglobin S in SCT donor blood, loss of deformability and increased osmotic fragility which could compromise their haemorheological properties and oxygen binding and delivery capacity [44, 45].

Storage of blood collected from SCT and asymptomatic malaria donors were significantly associated with red cell lysis and elevated plasma haemoglobin. On day of blood collection, donor plasma was free of haemoglobin as well as insignificant differences in potassium, sodium, LDH and chloride in all the donor groups. However at week 1, plasma haemoglobin was 2.4 times higher in SCT donor blood and 2.2 higher in asymptomatic malaria blood compared to sickle cell and malaria negative group. At week 3, plasma haemoglobin was 3.36 times and 2.36 times higher in SCT and asymptomatic malaria donor blood respectively, and at week 5, plasma haemoglobin was 2.2 times higher in SCT and 1.5 higher in asymptomatic malaria group. Excess plasma haemoglobin increased over time in the SCT and the asymptomatic malaria donor groups. At week 1, the percentage haemolysis in the SCT and asymptomatic malaria was more than the permissible level of 0.8%. Blood with % haemolysis of 0.8% is not recommended for clinical use [30]. Excess haemoglobin has been found to have negative influence on the intravascular nitric oxide (NO) metabolism after transfusion. Plasma haemoglobin has been found to be a potent scavenger of NO, the most important endogenous vasodilator. In view of this, transfusing blood with high concentration of plasma haemoglobin could decrease NO bioavailability, decreased organ perfusion, increased organ injury [46, 47] and increased mortality in patients with sepsis [48]. Patients with organ failure and patients with septic shock may worsen their condition when transfused with blood with high plasma haemoglobin content. Potassium increased in the SCT and asymptomatic malaria groups and continued till their respective levels were 4.8 and 3.4 times higher than the baseline at week 5, a factor far more than was observed in the sickle cell/malaria negative group. It is recommended to include malaria and sickle cells screening into donor screening protocols to prevent potassium and free haemoglobin overload. In addition, the clinical impact of transmitting malaria to the recipient, albeit asymptomatic in the donor, merits consideration with recommendations to prevent such transmissions [49].

Conclusion

Storage of SCT and malaria infected blood affected all the cell lines. At week 1, total white blood cells, neutrophils, red cells, haemoglobin and haematocrit began to fall significantly in SCT and asymptomatic donor blood. Significant elevation plasma haemoglobin, increase in % haemolysis above the permissible level of 0.8% and potassium elevation above the upper reference range for Ghanaian adults (5.2 mmol/L) [50] were observed. Significant reduction in red blood cells coupled with significant elevations in plasma haemoglobin, intracellular potassium and lactate dehydrogenase can led to the conclusion that significant number of red cells haemolysis in the experimental set up. This assumption was confirmed by steady elevation of % haemolysis over the storage weeks.

Limitations of the study

Malaria parasites were not quantified in the infected blood units. The analysis did not take into consideration the blood group and Rhesus phenotypes of the study units. The gender of the blood donors was unknown. Haemoglobin S was not quantified in the sickle cell trait donor blood.

Abbreviations

2,3 BPG: 

2,3-biphosphoglycerate

ANOVA: 

One-way analysis of variance

ATP: 

Adenosine triphosphate

Bas: 

Basophils

CPDA: 

Citrate Phosphate Dextrose Adenine

Eos: 

Eosinophils

fL: 

Fentoliter

GHS: 

Ghana Health Service

Hb: 

Haemoglobin

HCT: 

Haematocrit

LBR: 

Lymphocytes-to-basophils ratio

LER: 

Lymphocytes-to-eosinophils ratio

LMR: 

Lymphocytes-to-monocytes ratio

LNR: 

Lymphocytes-to-neutrophils ratio

Lymp: 

Lymphocytes

MCH: 

Mean cell haemoglobin

MCHC: 

Mean cell haemoglobin concentration

MCV: 

Mean cell volume

Mon: 

Monocytes

NBSG: 

National Blood Service Ghana

Neut: 

Neutrophils

P_LCR: 

Platelet large cell ratio

PCT: 

Plateletcrit

PDW: 

Platelet distribution width

pg: 

pictogram

Plt: 

Platelets

PMV: 

Mean platelet volume

RBC: 

Red blood cells

RDW_CV: 

Red cell distribution width coefficient of variation

RDW_SD: 

Red cell distribution width standard deviation

SCT: 

Sickle cell trait

SD: 

Standard deviation

SSA: 

sub-Saharan Africa

TTIs: 

Transfusion transmitted infections

TWBC: 

Total white blood cell

Declarations

Acknowledgements

The authors are thankful to the management and staff of National blood service, Ghana for collaborating with us in implementing the study. We are also grateful to Linda Baafi (Ga West Municipal Hospital Laboratory) for her voluntary participation in performing the biochemical analysis. Finally we are grateful to the National Malaria Control Programme Ghana for supplying us with malaria rapid diagnostic test kits.

Funding

The research was 100% funded by the corresponding author.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available in Harvard Dataverse repository, doi:https://doi.org/10.7910/DVN/RFBNFN

Authors’ contributions

AE, AP, EYA, AOD conceived, designed the study, collected the data, performed and validated the laboratory findings and drafted the manuscript. TDE performed the statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethical approval of this study was granted by National Blood Service Ghana (NBSGRD/18903/01) and Ghana Health Service Ethical Review Committee (GHS-REC002/03/18) approved the study. Consent to participate was not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana
(2)
School of Public Health, University of Ghana, Legon, Accra, Ghana
(3)
Department of Medical Laboratory Technology, University of Cape Coast, Cape Coast, Ghana

References

  1. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7(2):93–104.View ArticleGoogle Scholar
  2. Belizario VY, Saul A, Bustos MD, Lansang MA, Pasay CJ, Gatton M, Salazar NP. Field epidemiological studies on malaria in a low endemic area in the Philippines. Acta Trop. 1997;63:241–56.View ArticleGoogle Scholar
  3. Roucher C, Rogier C, Dieye-Ba F, Sokhna C, Tall A, Trape J-F. Changing malaria epidemiology and diagnostic criteria for Plasmodium falciparum clinical malaria. PLoS One. 2012;7:e46188.View ArticleGoogle Scholar
  4. da Silva-Nunes M, Ferreira MU. Clinical spectrum of uncomplicated malaria in semi-immune Amazonians: beyond the ‘symptomatic’ vs ‘asymptomatic’ dichotomy. Memorias Do Instituto Oswaldo Cruz. 2007;102(3):341–7.View ArticleGoogle Scholar
  5. Harris I, Sharrock WW, Bain LM, et al. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J. 2010;9:254.View ArticleGoogle Scholar
  6. Hoyer S, Nguon S, Kim S, Habib N, Khim N, Sum S, et al. Focused screening and treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia. PLoS One. 2012;7(10):e45797.View ArticleGoogle Scholar
  7. Owusu-Ofori A, Gadzo G, Bates I. Transfusion-transmitted malaria: donor prevalence of parasitaemia and a survey of healthcare workers knowledge and practices in a district hospital in Ghana. Malar J. 2016;15:234–41.View ArticleGoogle Scholar
  8. Mogtomo ML, Fomekong SL, Kuate HF, Ngane AN. Screening of infectious microorganisms in blood banks in Douala (1995-2004). Sante. 2009;19:3–8.PubMedGoogle Scholar
  9. Diop S, Ndiaye M, Seck M, Knight B, Jambou R, Sarr A, Dieye TN, Toure AO, Thiam D, Diakhate L. Prevention of transfusion transmitted malaria in endemic area. Clinical and biological transfusion. 2009;16:454–9.View ArticleGoogle Scholar
  10. Kinde-Gazard OJ, Gnahoui I, Massougbodji A. The risk of malaria transmission by blood transfusion at Cotonou, Benin. Cahiers Sante. 2000;10(6):389–92.PubMedGoogle Scholar
  11. Oladeinde BH, Omoregie R, Osakue EO, Onaiwu TO. Asymptomatic malaria among blood donors in Benin City Nigeria. Iranian J Parasitol. 2014;9(3):415–22.Google Scholar
  12. Aguiar KM, Maia CN. Prevalence of hemoglobin S in blood donors at the Hemocentro regional in the town of Montes Claros. Minas Gerais RBAC. 2011;43(4):284–7.Google Scholar
  13. Antwi-Baffour S, Asare RO, Adjei JK, Kyeremeh R, Adjei DN. Prevalence of hemoglobin S trait among blood donors: a cross-sectional study. BMC Res Notes. 2015;8:583.View ArticleGoogle Scholar
  14. Omotade OO, Kayode CM, Falade SL, Ikpeme S, Adeyemo AA, Akinkugbe FM. Routine screening for sickle cell haemoglobinopathy by electrophoresis in an infant welfare clinic. West Afr J Med. 1998;17:91–4.PubMedGoogle Scholar
  15. Tubman VN, Marshall R, Jallah W. Newborn screening for sickle cell disease in Liberia: a pilot study. Pediatr Blood Cancer. 2016;63:671–6.View ArticleGoogle Scholar
  16. Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I, Nsungwa J, Kiguli S, Ndugwa CM, Ware RE, Aceng JR. Burden of sickle cell trait and disease in the Uganda sickle surveillance study (US3): a cross-sectional study. Lancet Global Health. 2016;4:e195–200.View ArticleGoogle Scholar
  17. Ama V, Kengne AP, Nansseu NJ, Nouthe B, Sobngwi E. Would sickle cell trait influences the metabolic control in sub-Saharan individuals with T2D? Diabet Med. 2012;29:334–7.View ArticleGoogle Scholar
  18. Elguero E, Delicat-Loembet LM, Rougeron V, Arnathau C, Roche B, Becquart P, Gonzalez JP, Nkoghe D, Sica L, Leroy EM, Durand P, Ayala FJ, Ollomo B, Renaud F, Prugnolle F. Malaria continues to select for sickle cell trait in Central Africa. Proc Natl Acad Sci U S A. 2015;112:7051–4.View ArticleGoogle Scholar
  19. Grignani C, Iamamoto C, Goncalves T, Mashima D, et al. Prevalence of hemoglobin AS among blood donors from Londrina - Parana. RBAC. 2006;38(4):259–62.Google Scholar
  20. Goncalves LB, Duarte EHG, Cabral MD. Prevalence of hemoglobin S in blood donors in the hospital Dr. Agostinho Neto, Praia City – Cape Verde. Sci J Public Health. 2015;3(5):600–4.View ArticleGoogle Scholar
  21. Garba N, Danladi SB, Abubakar HB, Ahmad SG, Gwarzo MY. Distribution of Haemoglobin variants, ABO and Rh blood groups in blood donors attending Aminu Kano teaching hospital. Clin Med J. 2016;2(2):20–4.Google Scholar
  22. Adu P, Simpong DL, Takyi G, Ephraim RKD. Glucose-6-phosphate dehydrogenase deficiency and sickle cell trait among prospective blood donors: a cross-sectional study in Berekum, Ghana. Adv Haematol. 2016; https://doi.org/10.1155/2016/7302912.View ArticleGoogle Scholar
  23. Ghartimagar D. Rational clinical use of blood and blood products – a summary. J Pathol Nepal. 2017;7:1111–7.View ArticleGoogle Scholar
  24. Adias TC, Moore-Igwe B, Jeremiah ZA. Storage related Haematological and biochemical changes of CPDA-1 whole blood in a resource limited setting. J Blood Disorders Transf. 2012;3:124. https://doi.org/10.4172/2155-9864.1000124.View ArticleGoogle Scholar
  25. Cheesbrough M. Blood transfusion practice: blood donation and storage of blood, district laboratory practice in tropical countries. Low price edition. Cambridge Universal Press. 2002;2:352–3.Google Scholar
  26. Koch CG, Figueroa PI, Li L, et al. Red blood cell storage: how long is too long? Ann Thorac Surg. 2013;96(5):1894–9.View ArticleGoogle Scholar
  27. Bonaventura J. Clinical implications of the loss of vasoactive nitric oxide during red blood cell storage. Proc Natl Acad Sci U S A. 2007;104:19165–6.View ArticleGoogle Scholar
  28. Spinella PC, Sparrow RL, Hess JR, et al. Properties of stored red blood cells: understanding immune and vascular reactivity. Transfusion. 2011;51(4):894–900.View ArticleGoogle Scholar
  29. WHO. Guidelines on assessing donor suitability for blood donation. World Health Organization 2012. http://www.who.int/iris/handle/10665/76724. Assessed 7 Aug 2018.
  30. Sawant RB, Jathar SK, Rajadhyaksha SB, Kadam PT. Red cell hemolysis during processing and storage. Asian J Transfus Sci. 2007;1(2):47–51.View ArticleGoogle Scholar
  31. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229–39.View ArticleGoogle Scholar
  32. van de Watering L. Red cell storage and prognosis. Vox Sang. 2011;100:36–45.View ArticleGoogle Scholar
  33. Hess JR. Red cell changes during storage. Transfus Apher Sci. 2010;43:51–9.View ArticleGoogle Scholar
  34. Hess JR. An update on solutions for red cell storage. Vox Sang. 2006;91:13–9.View ArticleGoogle Scholar
  35. Antoniadou A, Giamarellou H. Fever of unknown origin in febrile leukopenia. Infect Dis Clin N Am. 2007;21(4):1055–90.View ArticleGoogle Scholar
  36. Friese CR. Chemotherapy-induced neutropenia: important new data to guide nursing assessment and management. Cancer Ther Support Care. 2006;4(2):21–5.Google Scholar
  37. Schortgen F. Fever in sepsis. Minerva Anestesiol. 2012;78(11):1254–64.PubMedGoogle Scholar
  38. Brandao MM, Saad O, Cezar CL, Fontes A, Costa FF, Barjas-Castro ML. Elastic properties of stored red blood cells from sickle trait donor units. Int J Transfusion Med. 2003. https://doi.org/10.1046/j.1423-0410.2003.00344.x.View ArticleGoogle Scholar
  39. Noguchi CT, Torchia DA, Schechter AN. Polymerization of hemoglobin in sickle cell trait erythrocytes and lysate. J Biol Chem. 1981;256:4168–71.PubMedGoogle Scholar
  40. Helzlsouer KJ, Hayden FG, Rogol AD. Severe metabolic complications in a cross country runner with sickle cell trait. JAMA. 1983;249:777–9.View ArticleGoogle Scholar
  41. Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sang. 2006;90(2):77–84.View ArticleGoogle Scholar
  42. Owusu-Ofori AK, Betson M, Parry CM, Stothard R, Bates I. Transfusion-transmitted malaria in Ghana. Clin Infect Dis. 2013;56(12):1735–41.View ArticleGoogle Scholar
  43. Raat NJ, Ince C. Oxygenating the microcirculation: the perspective from blood transfusion and blood storage. Vox Sang. 2007;93:12–8.View ArticleGoogle Scholar
  44. Kim-Shapiro DB, Lee J, Gladwin GT. Storage lesions: role of red blood cell breakdown. Transfusion. 2011;51:844–51.View ArticleGoogle Scholar
  45. Aubron C, Nichol A, Cooper DJ, Bellomo R. Age of red blood cells and transfusion in critically ill patients. Ann Intensive Care. 2013. https://doi.org/10.1186/2110-5820-3-2.View ArticleGoogle Scholar
  46. Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, Zhao X, Liu C, Reynolds H, Azarov I, Frizzell S, Meyer EM, Donnenberg AD, Qu L, Triulzi D, Kim-Shapiro DB, Gladwin MT. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011;26:465–76.View ArticleGoogle Scholar
  47. Minneci PC, Deans KJ, Zhi H, Yuen PS, Star RA, Banks SM, Schechter AN, Natanson C, Gladwin MT, Solomon SB. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest. 2005;115:3409–17.View ArticleGoogle Scholar
  48. Adamzic M, Hamburger T, Petrat F, Peters J, de Groot H, Hartmann M. Free hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome. Crit Care. 2012. https://doi.org/10.1186/cc11425. View ArticleGoogle Scholar
  49. Infectious disease testing for blood transfusions. NIH Consensus Panel on Infectious Disease Testing for blood transfusions. JAMA. 1995;274(17):1374–9.View ArticleGoogle Scholar
  50. Dosoo DK, Adu-Gyasi D, Kwara E, Ocran J, Osei-Kwakye, et al. Haematological and biochemical reference values for healthy adults in the middle belt of Ghana. PLoS ONE. 2012;7(4):e36308. https://doi.org/10.1371/journal.pone.0036308.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement